Global Cancer Diagnostics Partnering Directory 2010-2018: Updated Deal Trends, Players and Financials - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 25, 2019--The “Global Cancer Diagnostics Partnering 2010-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.
The Global Cancer Diagnostics Partnering 2012-2018 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.
The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1,200 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2012, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2012. The chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Diagnostics partnering and dealmaking since 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.
Cancer Diagnostics Partnering Terms and Agreements includes:
- Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2012
- Analysis of Cancer Diagnostics deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Cancer Diagnostics deals
- Access to Cancer Diagnostics contract documents
- Leading Cancer Diagnostics deals by value since 2012
- Most active Cancer Diagnostics dealmakers since 2012
Available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Cancer Diagnostics dealmaking
2.2. Cancer Diagnostics partnering over the years
2.3. Most active Cancer Diagnostics dealmakers
2.4. Cancer Diagnostics partnering by deal type
2.5. Cancer Diagnostics partnering by therapy area
2.6. Deal terms for Cancer Diagnostics partnering
2.6.1 Cancer Diagnostics partnering headline values
2.6.2 Cancer Diagnostics deal upfront payments7
2.6.3 Cancer Diagnostics deal milestone payments
2.6.4 Cancer Diagnostics royalty rates
Chapter 3 - Leading Cancer Diagnostics deals
3.2. Top Cancer Diagnostics deals by value
Chapter 4 - Most active Cancer Diagnostics dealmakers
4.2. Most active Cancer Diagnostics dealmakers
4.3. Most active Cancer Diagnostics partnering company profiles
Chapter 5 - Cancer Diagnostics contracts dealmaking directory
5.2. Cancer Diagnostics contracts dealmaking directory
Chapter 6 - Cancer Diagnostics dealmaking by technology type
Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 - Cancer Diagnostics deals by company A-Z
Appendix 2 - Cancer Diagnostics deals by stage of development
Appendix 3 - Cancer Diagnostics deals by deal type
Appendix 4 - Cancer Diagnostics deals by therapy area
Appendix 5 - Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/research/kv5sll/global_cancer?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190325005427/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH ONCOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/25/2019 08:58 AM/DISC: 03/25/2019 08:58 AM